Cornelia Handl
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Author Correction: Targeting the SHOC2-RAS interaction in RAS-mutant cancers.
Journal: Nature
Published: July 02, 2025
Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer.
Journal: Molecular cancer therapeutics
Published: May 21, 2025
High-throughput screen of 100 000 small molecules in C9ORF72 ALS neurons identifies spliceosome modulators that mobilize G4C2 repeat RNA into nuclear export and repeat associated non-canonical translation.
Journal: Nucleic acids research
Published: December 20, 2024
Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 29, 2021
A reversible haploid mouse embryonic stem cell biobank resource for functional genomics.
Journal: Nature
Published: November 17, 2016
A high-throughput screen to identify enhancers of ADAR-mediated RNA-editing.
Journal: RNA biology
Published: January 29, 2013
RNA-interacting proteins act as site-specific repressors of ADAR2-mediated RNA editing and fluctuate upon neuronal stimulation.
Journal: Nucleic acids research
Published: January 01, 2013
Showing 1-9 of 9
Last Updated: 09/26/2026